Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of DS-1471a in advanced solid tumors
jRCT2031230234Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of DS-1471a in Nonhematologic neoplasms, hepatocellular carcinoma (HCC) and Cirrhosis, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability of DS-1471a (dose escalation) and Overall safety of DS-1471a at the recommended dose(s) (dose expansion). Started Aug 2023; status: completed.
02
Drugs
DS-1471a
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)Cirrhosis
Beyond the preview
Go deeper on jRCT2031230234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230234.